Annual accounts
Unaudited abridged accounts
31/12/2026Filing deadline
Made up to 31/03/2025Due 31/12/2026
- Next accounts made up to
- 31/03/2026
- Last accounts made up to
- 31/03/2025
GYLDEN PHARMA LIMITED
Active- 09955881Copy
Copy
Registry details
Reference data exactly as held at Companies House.
Copy registry details
- Registered office
- 4 & 5 Dunmore Court Wootton Road, Abingdon, Oxfordshire OX13 6BH
- Classification (SIC)
- Research and experimental development on biotechnology (72.11 - SIC 2007)
- Accounts type
- Unaudited abridged
Company activity
The 4 most recent documents filed at Companies House.
Pre-Score for UK companies is coming soon
- 01/09/2026View PDF (2 pages)
Appointment of Mr Tony Flanagan as a director on 2026-07-09
- 20/08/2026View PDF (64 pages)
Registration of charge 099558810006, created on 2026-08-07
- 10/06/2026View PDF (64 pages)
Registration of charge 099558810004, created on 2026-05-21
- 04/02/2026View PDF (16 pages)
Confirmation statement made on 2025-08-07 with updates
Coming soon
What Pre-Score will tell you
- Whether the filed accounts are strengthening or weakening year on year.
- Whether this company files on time, and how often its record changes.
- How its officers and controlling parties connect to other UK companies.
Accounts and confirmation statement
The two filings Companies House requires every year, and where each one stands against its deadline today.
On schedule
Confirmation statement
Confirms the registry record is up to date
- Next statement date
- 07/08/2026
- Last statement dated
- 31/03/2025
Financial performance
The latest figures GYLDEN PHARMA LIMITED filed. Okredo holds filed accounts data for 2023–2025; the year-by-year record is on the financials page.
Net Assets
£-3.34M2025
-214.86%vs 20242024: £2.91M
Total Assets
£2.66M2025
-65.95%vs 20242024: £7.80M
Cash in Bank
£294.38K2025
-36.67%vs 20242024: £464.85K
Total Liabilities
£5.28M2025
48.66%vs 20242024: £3.55M
Employees
362025
-3vs 20242024: 39
Of the 4 measures with an earlier filing to compare against, 1 rose and 3 fell. Net assets moved furthest, down 214.86% on 2024. See the full financial analysis for GYLDEN PHARMA LIMITED.
The full financial record
Four ways through GYLDEN PHARMA LIMITED's filed accounts — the year-by-year numbers, the compound rates and the ratios behind them.
Cash in Bank · -65.2% a year (CAGR)Three-year trend, 2023–2025Every measure end to end across 2023, 2024 and 2025, with the compound rate behind each one.See what moved5 chartsCharts by indicator5 filed indicators plotted year by year, 2023–2025.Plot the figuresNothing estimatedRatios from the filed figures4 ratios computed from this company's own reported amounts, each shown against the year it was derived from.Check the ratios5 × 3 yearsEvery figure by yearAll 5 measures Okredo tracks across 3 reported years, exactly as filed.Open the table
Employees
Headcount as reported to Companies House for 2023–2025.
| Year | Employees | Change |
|---|---|---|
| 2025 | 36 | -3 |
| 2024 | 39 | +4 |
| 2023 | 35 | – |
Reported employee count increased from 35 in 2023 to 36 in 2025. See how headcount moved alongside the reported financials.
Credit report
It is a professional assessment of the company 's performance, revealing company's potential and risks, showing it's past experiences and revealing future prospects.
- Company potential
- Risk indicators
- Past performance
- Future prospects
Officers
19Directors, secretaries and other appointed officers, with the period each has served.
| Person | Role | Period | Connected companies |
|---|---|---|---|
| Director | 25/08/2016–08/12/2019 | 6 | |
| Director | 17/08/2022–Present | 6 | |
| Director | 16/04/2021–17/08/2022 | 8 | |
| Director | 25/08/2016–04/01/2018 | 47 | |
| Director | 15/03/2018–22/11/2019 | 14 | |
| Director | 18/01/2016–Present | 5 | |
| Director | 18/01/2016–Present | 6 | |
| Director | 24/09/2020–05/01/2024 | 0 | |
| Director | 03/09/2019–Present | 0 | |
| Director | 01/08/2018–14/11/2025 | 0 | |
| Director | 17/08/2022–Present | 0 | |
| Director | 25/08/2016–23/04/2018 | 1 | |
| Director | 01/04/2017–04/01/2021 | 0 | |
| Director | 10/08/2017–17/08/2022 | 0 | |
| Director | 08/12/2022–03/09/2024 | 0 | |
| Director | 27/09/2023–27/08/2026 | 0 | |
| Director | 05/01/2024–Present | 0 | |
| Director | 27/08/2026–Present | 0 | |
| Director | 09/07/2026–Present | 0 |
Persons with significant control
1Individuals or entities with significant control over the company, as declared to Companies House.
| Person | Period | Connected companies |
|---|---|---|
| 06/04/2016–Present | 5 |
Filing history and recent activity
Every document on the Companies House record, newest first.
- Filings on record
- 39 Since 17/08/2022
- Last 12 months
- 9 -3 vs the year before
- Most recent filing
- 01/09/2026 less than a month ago
What changed in the last year
- Officer changes (2)Latest 01/09/2026
- Charges and mortgages (4)Latest 20/08/2026
- Confirmation statementLatest 04/02/2026
- Accounts filedLatest 31/12/2025
- Share capitalLatest 22/10/2025
Filing timeline
- 01/09/2026View PDF (2 pages)
Appointment of Mr Tony Flanagan as a director on 2026-07-09
- 20/08/2026View PDF (64 pages)
Registration of charge 099558810006, created on 2026-08-07
- 10/06/2026View PDF (64 pages)
Registration of charge 099558810004, created on 2026-05-21
- 04/02/2026View PDF (16 pages)
Confirmation statement made on 2025-08-07 with updates
- 31/12/2025View PDF (10 pages)
Unaudited abridged accounts made up to 2025-03-31
- 30/12/2025View PDF (1 pages)
Termination of appointment of Sergio Pagani as a director on 2025-11-14
- 26/11/2025View PDF (64 pages)
Registration of charge 099558810003, created on 2025-11-07
- 22/10/2025View PDF (4 pages)
Statement of capital following an allotment of shares on 2025-10-09
- 30/09/2025View PDF (64 pages)
Registration of charge 099558810002, created on 2025-09-10
- 23/07/2025View PDF (11 pages)
Unaudited abridged accounts made up to 2024-03-31
- 19/05/2025View PDF (2 pages)
Resolutions
- 13/05/2025View PDF (58 pages)
Memorandum and Articles of Association
Showing 12 of 39 filings
See when the next accounts and confirmation statement are due
Similar companies
13 UK companies are similar to GYLDEN PHARMA LIMITED, sharing the same company status (Active), the same industry sector and activity group (Research and experimental development on biotechnology) and a comparable number of employees. The 5 closest matches are shown below to help you compare competitors and industry peers.
PHARMIDEX PHARMACEUTICAL SERVICES LIMITED
Active167-169 Great Portland Street, Fifth Floor, London W1W 5PF
- Activity
- Research and experimental development on biotechnology
- Company no.
- 04441512
- Incorporated
- 17/05/2002
- Employees
- 33
YOUSEQ LTD
Active8 Moorside Place, Moorside Road, Winchester, Hampshire SO23 7FX
- Activity
- Research and experimental development on biotechnology
- Company no.
- 11595406
- Incorporated
- 29/09/2018
- Employees
- 39
CCM TECHNOLOGIES LIMITED
ActiveKingston House Lydiard Fields, Great Western Way, Swindon SN5 8UB
- Activity
- Research and experimental development on biotechnology
- Company no.
- 07633047
- Incorporated
- 13/05/2011
- Employees
- 30
EXCELLERATE BIOSCIENCE LIMITED
ActiveNg2 Business Park, 21 The Triangle, Nottingham NG2 1AE
- Activity
- Research and experimental development on biotechnology
- Company no.
- 10228159
- Incorporated
- 13/06/2016
- Employees
- 31
GURU SYSTEMS LIMITED
ActiveUnit 05.G01 The Leather Market 11-13 Weston Street, Bermondsey, London SE1 3ER
- Activity
- Other research and experimental development on natural sciences and engineering
- Company no.
- 08172055
- Incorporated
- 08/08/2012
- Employees
- 30
About GYLDEN PHARMA LIMITED
A short description of the company, written from its Companies House record.
GYLDEN PHARMA LIMITED is a private limited company registered in the United Kingdom, based in 4 & 5 Dunmore Court Wootton Road, Abingdon, Oxfordshire OX13 6BH. Companies House classifies its business as Research and experimental development on biotechnology. It has been on the register for 10 years 8 months.
The register currently records it as active. Its 2025 accounts report net assets of £-3.34M and 36 employees.
GYLDEN PHARMA LIMITED: frequently asked questions
Answered from this company's own registry record and filed figures.
What does GYLDEN PHARMA LIMITED do?
Companies House records GYLDEN PHARMA LIMITED under one registered business activity: Research and experimental development on biotechnology (72.11 - SIC 2007).
Is GYLDEN PHARMA LIMITED still active?
GYLDEN PHARMA LIMITED is recorded as active on the Companies House register, and has been on it since 18/01/2016.
What are GYLDEN PHARMA LIMITED's latest reported financials?
The most recent accounts Okredo holds cover 2025 and report net assets of £-3.34M, total assets of £2.66M, cash in bank of £294.38K and total liabilities of £5.28M.
When did GYLDEN PHARMA LIMITED last file with Companies House?
The most recent document on the record is dated 01/09/2026: Appointment of Mr Tony Flanagan as a director on 2026-07-09, less than a month ago.
When are GYLDEN PHARMA LIMITED's next filings due?
On the current registry record, accounts are due by 31/12/2026.
Who runs GYLDEN PHARMA LIMITED?
Companies House lists 19 officers (8 currently in post) and 1 person with significant control.